Identification of genetic alterations through next generation sequencing (NGS) can guide decision‐making by providing insights on myeloid and lymphoid malignancies through targeted NGS, particularly with rare fusions. In this webinar, HSL presents case studies on their experience implementing Archer FUSIONPlex™, VARIANTPlex™, and IMMUNOVerse™ assays for profiling haematological malignancies. Learn why they chose the panels, how they were implemented in the lab, and their experience with the chemistry, workflows, and analysis software.
Molecular Haematology Operations Manager
Health Service Laboratories
Director, Custom NGS Products
Integrated DNA Technologies